Q-omics provides the consensus-scored NIBAN1 profile across patient tissues and cancer cell-line models. NIBAN1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, NIBAN1 is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, NIBAN1 protein abundance shows 26,141 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BLCA, and GBM as cancer lineages where NIBAN1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NIBAN1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NIBAN1 survival associations across molecular data types. NIBAN1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (8) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NIBAN1 RNA expression–survival associations across cancer types. High NIBAN1 expression shows unfavorable associations in BLCA, KICH, MESO and LGG, but favorable associations in LUAD and UVM. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for NIBAN1 RNA expression.
This table summarizes NIBAN1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NIBAN1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NIBAN1 shows lower tumor expression in BLCA, COAD, LUAD, UCEC and BRCA and higher tumor expression in KIRC. The BLCA box plot shows higher NIBAN1 RNA expression in normal versus tumor tissue (log2 FC = −2.872, t-test p < 0.001).
This table shows molecular features associated with NIBAN1 in patient tissues and cancer cell lines. In patient samples, NIBAN1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NIBAN1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Lymphoma.
